Welcome to #KCRS20!
October 22, 4:00-7:00 p.m. EST
October 23, 8:00-11:00 a.m. EST
KidneyCAN is proud to announce the 2nd annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.
Building Global communication and collaboration
in the research community
Welcome to #KCRS20!
October 22, 4:00-7:00 p.m. EST
October 23, 8:00-11:00 a.m. EST
KidneyCAN is proud to announce the 2nd annual Kidney Cancer Research Summit, a meeting focused on basic and translational science, as well as cutting edge translational research. This work is fueled by the funding from the Department of Defense CDMRP – KCRP.
Building Global communication and collaboration in the research community
Registration Open
Given the complications of COVID-19, #KCRS20 will be a virtual conference. Join us as we continue to fight for a cure!
Registration for this event is now open for Academic/Research attendees and Industry Representatives.
#KCRS20 Agenda
We have an exciting program planned!
Thursday, October 22nd
4:00-7:00 p.m. EST
Registration
3:00-4:00 EST
Event registration opens at 3:00 p.m. EST. Please use this opportunity to visit our sponsor pages!
Welcome
4:00-4:10 p.m. EST
Welcome to #KCRS20! Introduction to our event, overview of topics and speakers, and information for navigating the virtual platform.
Keynote Presentation: Insights into Renal Cancer from VHL
4:10-5:00 p.m. EST
Dr. William G. Kaelin, Jr., Nobel Laureate
Dana Farber Cancer Institute
The Next Frontier: New Molecular Targets for Kidney Cancer
5:00-6:00 p.m. EST
Moderated by Eric Jonasch, MD Anderson Cancer Center, and Naomi Haas, University of Pennsylvania.
“Therapeutic Targeting of Cystine Addiction of RCC”
Jen Tsan Chi, Duke University
“TBK1 Serves as a Novel Therapeutic Target in Kidney Cancers with VHL Loss”
Qing Zhang, University of Texas Southwestern
“Targeting IGF1R Signaling in MTAP-Deficient Kidney Cancer”
Ching-Hsien Chen, University of California Davis
“Studying BAP1 in Regulating Glucose Dependency in Renal Cancer: Mechanisms and Preclinical Translation”
Boyl Gan, MD Anderson Cancer Center
Getting the Right Therapies to the Right Patients: Emerging Biomarkers for Kidney Cancer
6:00-7:00 p.m. EST
Moderated by Sabina Signoretti, Dana Farber Cancer Institute.
“Characterizing and Targeting the Microenvironmental Barriers to Immunotherapeutic Response in RCC: Team Research”
Ari Hakimi & Tim Chan, Memorial Sloan Kettering Cancer Center
“Endogenous Retrovirus Expression, Chromatin Abnormalities, and Response to Immune Checkpoint Blockade in Clear Cell RCC”
Shridar Ganesan, Rutgers Cancer Institute
“Host Immune Signatures as Therapy Response Biomarkers in Metastatic Renal Cell”
Ziad Bakouny, Dana Farber Cancer Institute
“Development and Testing of Circulating-Free Methylation DNA as a Prognostic Biomarker for Recurrent Kidney Cancer”
[Presenter TBD]
Friday, October 23rd
7:00-11:00 a.m. EST
Registration
7:00-11:00 a.m. EST, followed by optional CME
Event registration opens at 7:00 a.m. EST. Please use this opportunity to visit our sponsor pages!
Welcome
8:00-8:10 a.m. EST
Welcome to Day Two of #KCRS20! Introduction to today’s topics and speakers, and information about the optional CME.
Best of 2020: Including Updates from ESMO
Moderated by Toni Choueiri, Dana Farber Cancer Institute.
“Translational Science Updates from ESMO”
Tom Powles, Barts Cancer Centre
“Important Clinical Updates from ESMO”
Laurence Albiges, Institut Gustave_Roussy
“The Ever-Changing Clinical Landscape of Kidney Cancer Therapies: Updates and Ongoing Trials”
Robert Motzer, Memorial Sloan Kettering Cancer Center
Break
Please use this opportunity to grab a drink or snack and visit our sponsor pages!
The Next Generation of Immune Therapies
10:00-11:00 a.m. EST
Moderated by Hans Hammers, University of Texas Southwestern.
“Targeted Pro-Inflammatory Prodrugs for the Immunotherapy of Kidney Cancer”
Hans Hammers, University of Texas Southwestern
“Oncolytic Single-Cycle Replicating Immunotherapies for Kidney Cancer”
Michael Barry, Mayo Clinic
“Personalized T-Cell Immunotherapy for Renal Cell Carcinoma”
Shreeran Akilesh, University of Washington
“Lessons in Immunotherapy Failures”
[Presenter TBD]
Lunch
11:00 a.m. – 12:00 p.m. EST
Please use this opportunity to eat lunch and visit our sponsor pages!
Optional CME Course
12:00-1:30 p.m. EST
An optional CME course will be presented after the lunch break.
On-Demand Content
View pre-recorded sessions here!
The Next Frontier: New Molecular Targets for Kidney Cancer
Video content to come — stay tuned!
“Profilin 1 as a Novel Target in Patients with RCC”
Partha Roy, University of Pittsburgh
“Functionally Characterizing the Enhancer Cistrome in Advanced Human Kidney Cancer”
[Presenter TBD]
Novel Models for Kidney Cancer Research
Video content to come — stay tuned!
“Unlocking the Human Relevance of a New Genetic Papillary RCC Mouse Model”
Richard Link, Baylor College of Medicine
“Modeling Spatial Ecology in Clear Cell Renal Cell Carcinoma Model: A Novel Tool to Support Drug Sequencing Decisions”
Brandon Manley, H. Lee Moffitt Cancer Center
“Kidney Cancer (DFCI) Model”
[Presenter TBD]
“Kidney Cancer (UTSW) Model”
[Presenter TBD]
Evolving Imaging Methods for Improved Diagnosis and Response Prediction
Video content to come — stay tuned!
“Noninvasive Diagnostic Assessment of Kidney Cancer Using Hyperpolarized 13C L-Tryptophan”
Lloyd Lumata, University of Texas at Dallas
“Immune Checkpoint Targeted Immuno-PET to Identify Therapy-Induced Adaptive Resistance: Research Partnerships”
Xiankai Sun, University of Texas Southwestern
“Quantitative CT Biomarkers to Predict Metastatic RCC Response to Antiangiogenic Therapy”
Andrew Smith, University of Alabama at Birmingham
Germline Genetics and Implications
Video content to come — stay tuned!
“Introduction to RCC Germline Genetics”
[Presenter TBD]
“Biological Determinants of Kidney Cancer Health Disparities”
Khadijah Mitchell, Lafayette College
“First Functional Analysis of an Inherited SETD2 Mutation Associated with RCC”
Rebecca Arnold, Emory University
Variant Kidney Cancer Histologies: Characterization and Therapeutic Targeting
Video content to come — stay tuned!
“The Pathogenesis and Therapy of Chromophobe RCC: A Single-Cell RNA Sequencing Approach”
Elizabeth Henske, Brigham & Women’s Hospital
“Defining the Role of Beta-Catenin Activation in Wilms Tumor”
Keri Drake, University of Texas Southwestern
“Therapeutic Targeting of FLCN-Deficient Renal Cancers”
Othon Iliopoulos, Massachusetts General Hospital
“Molecular Characterization and Therapeutic Targeting of TFE3 Fusion Kidney Cancers”
[Presenter TBD]
#KCRS20 Partners
KidneyCAN has partnered with industry sponsors to support #KCRS20. Look for the resources from our partners to be shared here in the weeks to come!
KidneyCAN is a registered 501(c)(3) nonprofit grassroots organization dedicated to funding and finding a cure for kidney cancer.
Contact Us
KidneyCAN, 8327 Germantown Avenue, Philadelphia, PA 19118